Interleukin-33 as a Potential Therapeutic Target in Gastric Cancer Patients: Current Insights

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Gastric cancer (GC) is a leading cause of cancer mortality globally.
• Current treatments for advanced GC have limited efficacy.
• Understanding molecular signaling pathways is crucial for novel therapeutic targets.

Purpose of the Study:

• To review the multifaceted role of Interleukin 33 (IL-33) in gastric cancer.
• To elucidate the functions of IL-33 in GC development and progression.
• To identify potential therapeutic strategies targeting IL-33 in GC.

Main Methods:

• Literature review summarizing current research on IL-33 in gastric cancer.
• Analysis of IL-33's dual cytokine and nuclear factor activities.
• Examination of IL-33's interaction with its receptor ST2L and downstream signaling.

Main Results:

• IL-33 signaling can promote gastric cancer through immune cell recruitment and metaplasia.
• IL-33 may induce stem cell-like and epithelial-mesenchymal transition (EMT) properties in GC cells.
• The precise role of IL-33 in GC is still under investigation, with some conflicting findings.

Conclusions:

• IL-33 exhibits pro-tumorigenic functions in gastric cancer.
• Disrupting IL-33 signaling presents a potential therapeutic avenue for GC prevention and treatment.
• Further research is warranted to fully understand and exploit IL-33's role in GC.